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We assess the impact of cardiovascular disease (CVD) mortality on economic growth, using a 
dynamic panel growth regression framework taking into account potential endogeneity 
problems. We start from a worldwide sample of countries for which data was available and 
detect a non-linearity in the influence of working age CVD mortality rates on growth across 
the per capita income scale. We then split the sample (according to the resulting income 
threshold) into low- and middle-income countries on one hand, and high-income countries on 
the other hand. In the latter sample we find a robust negative contribution of increasing CVD 
mortality rates on subsequent five-year growth rates. Not too surprisingly, we find no 
significant impact in the low- and middle-income country sample. 
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1 Introduction 
There is abundant evidence that cardiovascular disease (CVD) and non-communicable disease 
(NCD) more generally are no longer mere “diseases of affluence”. CVD kills nearly three 
times as many people in developing countries each year as HIV, tuberculosis, and malaria 
combined, and it accounts by far for the predominant share of overall mortality in developed 
countries. The main question that this paper seeks to address is therefore: are CVDs bad for 
economic growth? 
 
Theoretically, ill-health may not only reduce the supply and productivity of labor but can also 
impede human capital accumulation. Hence, a poor health status would negatively impact 
individual and social welfare both through the utility function and through a lower growth rate 
(and level) of national per capita income. The empirical literature on the role of health in 
explaining the variation in growth rates (or levels) of per capita incomes has grown 
substantially in recent years
2 – with the overall finding that health – when measured as life 
expectancy or adult mortality – enters as one of very few robust predictors of subsequent 
economic growth (Levine and Renelt 1992; Sala-i-Martin et al. 2004)
3. However, research in 
this area has so far focused either on general health indicators (i.e., life expectancy, adult 
mortality) or on specific diseases most characteristic of developing countries. As for the latter, 
there is, for instance, evidence on the impact of malaria (Gallup and Sachs 2001), HIV/AIDS 
(Dixon et al. 2001), malnutrition (Weil 2005), and tuberculosis (Delfino and Simmons 1999) 
on economic growth. 
 
                                                 
2 For extensive overviews see e.g. Commission on Macroeconomics and Health (2001) and López-Casasnovas et 
al. (2005). 
3 A recent qualification is by Acemoglu and Johnson (2006).   3
While the vast majority of studies examines a worldwide sample, it is not obvious whether the 
same relationship exists between health and economic growth for rich countries as it does for 
poor countries. Indeed, Rivera and Currais (1999a, b), for example, find that an increase in 
life expectancy reduces economic growth rates among OECD countries.
4 Therefore, it seems 
important to pay particular attention to whether there are sample breaks and, if so, where they 
occur. To the best of our knowledge, only Bhargava et al. (2001) determine endogenously the 
sample breakpoint. They establish a threshold in terms of per capita income below which a 
higher adult survival rate is positively affecting growth. Above the (relatively low) per capita 
income threshold the relationship switches signs. 
 
To the best of our knowledge, no study has hitherto explored in some more depth the growth 
implications of the particular type of diseases that account for the largest disease burden in 
high-income countries, and for an already substantial and fast growing burden in developing 
countries, i.e., non-communicable disease (NCD)
5. The present paper fills this gap by 
examining the growth impact of cardiovascular disease (CVD), which is the disease that 
accounts for the greatest share of the NCD burden
6. We follow Bhargava et al. (2001) in 
taking into particular account the potential difference between developed and developing 
countries, regarding the growth impact of this specific health indicator.  
 
A priori, there is a lot to suggest that CVD might “matter” in economic terms.  
First, a series of recent reports has highlighted the substantial and growing public health 
importance of CVD (Jamison et al 2006; WHO 2005). A distinctive feature of CVDs (as well 
as some other non-communicable diseases) is that it causes morbidity and, hence, potential 
                                                 
4 However, Knowles and Owen (1995, 1997) find a positive correlation when replacing life expectancy by public 
health expenditure as a proxy for “health”. 
5 It has come to be widely accepted that the term “non-communicable disease” is a somewhat unfortunate choice. 
Increasingly, NCDs are being called “chronic disease” in light of long duration. (WHO 2005). 
6 According to latest WHO estimates CVDs accounted for 51% of overall mortality due to NCDs in low- and 
middle-income countries in 2005 (WHO 2006).   4
productivity decline years or even decades ahead of death
7. Second, a recent review of the 
economic impact of chronic disease has synthesized a significant number of cost-of-illness 
studies highlighting the substantial economic magnitudes involved in CVDs and the related 
risk factors (Suhrcke et al. 2005)
8. Third, the same review also summarized the 
microeconomic evidence on the labor market impact of chronic disease (and relevant risk 
factors).
9  
The question then imposes itself whether on top of the obvious epidemiological evidence, the 
cost of illness as well as the microeconomic evidence, there may also be a macroeconomic 
impact of CVDs. 
 
The present paper assesses the impact of CVD mortality on economic growth, adopting a 
panel growth regression framework, taking into account the potential endogeneity of CVDs. 
We are thereby careful in proxying CVD disease by its mortality rate among the working age 
cohort to capture as close as possible the impact of the disease on worker productivity. As in 
Bhargava et al. (2001), we start from a worldwide sample of countries for which data was 
available and detect a non-linearity in the influence of CVD on growth across the per capita 
income scale while controlling at the same time for more general health indicators. Then, we 
split the sample (according to the resulting income threshold) into low- and middle-income 
countries on one hand, and high-income countries on the other hand. In the latter sample we 
find a fairly robust negative contribution of increasing CVD mortality rates on subsequent 
five-year growth rates. Not surprisingly, we find no significant impact in the low- and middle-
income country sample. Taken literally, this implies that as countries grow richer they should 
seek to avoid that what used to be “diseases of affluence” does not end up as obstacles to 
(even greater) affluence. 
                                                 
7 This feature of CVDs also helps prevent allegations of reverse causality in our growth regression framework 
adopted below. 
8 See also Petersen et al (2005) for cost-of-illness estimates for all European Union member-states. 
9 On the economic consequences of CVDs see also Leeder et al. (2004).   5
 
The paper is structured as follows. Section 2 argues why CVD may be of particular 
importance in explaining income growth; section 3 describes the empirical methodology, 
section 4 presents and discusses the results. The final section concludes. 
 
 
2 Cardiovascular disease 
Why should cardiovascular disease matter for growth? Traditionally, just like non-
communicable diseases (NCDs) in general, CVDs have been considered by many as a 
“disease of affluence” – a consequence rather than a determinant of economic development. 
Moreover, the economic importance of NCDs (or CVDs in particular) has typically been 
downplayed as it (allegedly) affected predominantly people beyond retirement age.  
 
However, such notions of “conventional wisdom” fail to correctly characterize the 
contemporary epidemiological reality (Ezzati et al. 2005). First, NCDs already account for a 
larger share of mortality than communicable diseases and child and maternal disease taken 
together in all but the low income countries (see Figure 1). The richer the country, however, 
the greater the share of mortality accounted for by NCDs (and CVDs), which is why we 
expect stronger evidence on the impact of CVD on income growth for high-income countries 
than for low- and middle-income countries.
10 
 
Second, a very large share of NCD and CVD mortality is actually occurring well before 
retirement age (see Table 1). For example, 31% of all CVD caused death falls into the age 
group younger than 65 years, even in low- and middle-income countries. When taking into 
                                                 
10 Figure 1 only gives a recent snapshot of the disease burden at one point in time. It is important to emphasise 
that recent trends unambiguously show the morbidity and mortality burden caused by CVDs (and NCDs) 
progressing at an increasing speed not only in high-income countries but also in developing countries (Jamison 
et al, 2006).   6
consideration that death is usually preceded by a period of morbidity, the disease burden falls 
even more into the working age group. Almost two thirds of the mortality and morbidity 
(measured in Disability Adjusted Life Years – DALYs) due to CVDs occurs before age 65. 
 

































Table 1: Share of disease burden falling before age 65, low and middle income countries 
Disease category  Deaths  DALYs 
All NCDs  39%  81% 
Cardiovascular disease  31%  62% 
Communicable, maternal, 
perinatal and nutritional 
conditions 
89% 98% 
Source: WHO (2006). 
 
 
In light of this purely epidemiological evidence, it is not hard to imagine that there could well 
be a significant macroeconomic impact on labor supply, productivity, population growth, 
physical and human capital accumulation, and income in levels and growth rates. Labor   7
supply is directly affected since morbidity usually precedes death. Affected workers do not 
only drop out of the workforce, but impose a health care burden on others reducing income 
and growth, for example, through distortionary taxation or health insurance premia to finance 
health care. Workers in ill-health may still work but at a reduced effort level, since the disease 
may affect their work ambition and durability, which in turn reduces average worker 
productivity. Worker productivity has not only an impact on the level of income but also on 
its growth rate, because worker productivity affects immediately the return on investment, 
capital accumulation and eventually income growth. Not only morbidity, but also life 
expectancy itself may have an impact on income in levels and growth. Since education is a 
fixed cost in the early stage of life that needs to be covered by education-wage premia over all 
later stages of working life, the return to human capital accumulation is negatively affected by 
a reduction in the expected working-age lifetime (Kalemli-Ozcan et al. 2000). A lower rate of 
human capital accumulation then again leads to reduced income growth. An increase of life 
expectancy also influences the fertility choice according to Soares (2005) which in turn 
affects the population growth rate and income growth (in a world with less than perfect 
international capital markets). 
 
Figure 1 has suggested that despite its unquestionable global importance there may be 
significant differences between developing and developed countries in that communicable 
diseases are relatively more important for low-income countries and non-communicable 
diseases relatively more important for high-income countries. Since the study of Bhargava et 
al. (2001) pays particular attention to such structural breaks, we adopt its methodology and its 
control variables as a starting point.   8
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We follow Bhargava et al. (2001) in applying panel data in five year intervals from the year 
1960 until 2000 to avoid business cycle regularities to influence our results. The data are PPP-
adjusted GDP per capita and its 5-year time lag, the average degree of openness in between   9
1965 and 1990 from Gallup and Sachs (1998), and 5-year lagged values of the investment 
rate, fertility rate, adult mortality rate and our variable of interest: CVD mortality rate of the 
working age population. We also use an interaction term of CVD mortality with lagged GDP 
per capita. Instead of the adult mortality rate, Bhargava et al. (2001) have used the adult 
survival rate, which is not publicly available.  The data description, variable abbreviations, 
and sources are summarized in Table 2 that contains also additional variables that entered our 
analysis beneath. 
 
Table A1 in the appendix gives summary statistics of each variable. Since we estimate a 
dynamic panel regression, and it is known that a standard OLS estimator is inconsistent in this 
case, we pay particular attention to the estimation methodology that is described next. 
 
3 Empirical methodology 
A panel growth regression model can be written in a general form as follows: 
it i t i t i
p
l
l t i l it z x y y ε η β β β α + + ⋅ + ⋅ + + ⋅ = − −
=
− ∑ 1 , 2 1 , 1 0
1
, ,       for    t=1+p…T,  (1) 
where yit is GDP per capita of country i at time t=1..T, xit is a vector of pre-determined control 
variables, zit is a vector of exogenous control variables,  i η  an i.i.d. country-specific random 
effect, it ε  is the usual i.i.d. error term (possibly heteroscedastic but not autocorrelated), and 







11 The initial 
value of the dynamic process is assumed to be an i.i.d. random deviation from the steady state 
value. The time dimension of panel growth regressions was typically chosen to be 5 or 10 
                                                 






l α , then the Blundell and Bond (1998) estimator is still consistent but no longer 
efficient, as has been shown in Binder et al. (2003). The convergence rate can be obtained as  1 1 − α  if p=1.   10
year periods to avoid short term business cycle components to influence the convergence rate 
(see e.g. Islam, 1995, Caselli et al., 1996, and Bond et al. 2001). 
 
A pre-determined (endogenous) covariate is defined as a random variable that is allowed to 
depend on past values of GDP per capita, but not on future GDP per capita. When allowing 
for pre-determined variables xit, the reverse causality from past values of GDP to xit is fully 
controlled for and the regression coefficient measures only the marginal effect from 
contemporary values of xit to future values of GDP per capita. Hence, a regression coefficient 
of a pre-determined variable measures causality in a Granger sense. 
 
For example, when assuming our variable of interest CVD to be pre-determined, we take into 
consideration that the population in richer societies has a higher probability of CVD. The 
regression coefficient, however, filters this reverse causality, and measures only the impact 
that CVD today has on future economic growth assuming that today’s occurrence of CVD is 
not depending on the prospect of future growth. However, the last assumption is not a binding 
constraint for our estimations, since it is not perceivable that life style adjusts before a change 
of income. 
 
Nickel (1981) has shown that an FE-estimator on (1) is inconsistent, when the time dimension 
is small, because there is a correlation of the group mean of the error term with the lagged 
dependent variable. Moreover, Trognon (1978) has shown that an OLS-estimator is also 
inconsistent, because the lagged dependent variable is correlated with the random effect. The 
direction of bias is generally not known without further information on the covariance matrix 
of all variables, although closed form solutions of the bias term exist.  
   11
Arellano and Bond (1991) recommend a one-step GMM-system estimator built on the 
following generalized moment conditions 
[ ] 0
' = ∆ i i W E ε  (2) 
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and  i ε ∆  denotes the (T-1-p)-dimensional vector of first-differenced error terms. All elements 
of the matrix Wi are valid instruments, because the lagged values of 2
nd and higher order of 
the dependent variable are not correlated with the first differenced error term, where first-
differencing whipes out the random effect. 
 
Blundell and Bond (1998) point out a weak-instrument problem (see Staiger and Stock, 1997, 
and Hahn and Hausman, 2002) that is most severe, whenever the dependent variable follows a 
near-unit root process or whenever the variance of the random effect is large relative to the 
variance of the error term, and suggest the additional moment conditions 
() [ ] 0 ' 1 , = + ∆ − it i t i y E ε η , (3) 
for t=p+1,…,T. The moment conditions in (3) hold, because lagged first differences of the 
dependent variable have differenced out the random effect and are not correlated with the 
contemporary error term. 
 
As usual in GMM estimation, the generalized moments (2) and (3) are replaced by their 
sample estimates and the GMM criterion function over all moment conditions is minimized 
with respect to all regression coefficients. Because the moment conditions (2) and (3) imply 
that observations are taken twice (in level and first differences), the applied solution is   12
identical to a system GMM estimator on a regression system of variables in levels and first 
differences. 
 
The covariance matrix of the GMM criterion function depends on the regression estimates. 
Hence, a heteroscedasticity consistent one-step estimator replaces the estimated covariance 
matrix with an approximation (see Roodman, 2004, for details). A heteroscedasticity 
consistent two-step estimator uses the estimates of the second step to obtain an estimated 
moment covariance that is used to minimize the GMM criterion function again and obtain the 
more efficient two-step estimator. However, Arellano and Bond (1991) point out that there is 
a severe small sample bias of the covariance matrix of the regression coefficients, when 
applying the two-step GMM system estimator and recommend to use the one-step estimator. 
However, Windmeijer (2000) has developed a small sample correction to the regression 
coefficient covariance matrix. Hence, we will apply both the one-step system GMM estimator 
and the two-step system GMM estimator with small sample correction. 
 
Bhargava et al. (2001) apply the Bhargava and Sargan (1983) dynamic panel estimator. While 
this estimator has similar statistical large sample properties and we are not aware of small 
sample Monte Carlo study comparisons, we prefer the Blundell and Bond (1998) estimator 
both, because its software is available for free
12 and a larger number of applications exist such 
that more experience has been gained in applications. 
 
 
                                                 
12 We thank David Roodman for his STATA 8.0 module xtabond2, which is used in this study. Of course, we 
take sole responsibility for any possible remaining errors in the program.   13
4 Results 
 
We begin with a GMM one-step system estimation of the baseline specification of Bhargava 
et al. (2001), i.e. we regress GDP per capita on its 5-year time lag
13, the average degree of 
openness in between 1965 and 1990 from Gallup and Sachs (1998), and 5-year lagged values 
of the investment rate, fertility rate, adult mortality rate and our variables of interest: CVD 
mortality rate of the working age population and its interaction term with lagged GDP per 
capita. Instead of the adult mortality rate Bhargava et al. (2001) have used the adult survival 
rate, which is not publicly available. A dummy variable for tropic countries as well as an 
interaction term of the survival rate and the lagged income level is left out, too, because both 
variables turned out to be insignificant for our sample, which is due to smaller coverage of 
observations caused by missing observations on CVD. There are few countries in our sample 
that are below the income threshold reported in Bhargava et al. (2001) which splits the sample 
into one group of countries with a positive and another with a negative impact of the survival 
rate on growth. Moreover, there are few countries in tropic regions that report CVD mortality 
rates. 
 
The first specification in Table 3 uses the 1-step GMM-system estimator with the first and 
second lag of the instrumented covariates as instruments. When choosing the lag number of 
instruments, a trade-off was taken into consideration between increased efficiency of 
additional instruments and an aggravation of the weak-instrument problem, if additional time 
lagged instrumental variables are only weakly correlated with the instrumented covariate.
14 
                                                 
13 This is equivalent to estimating the growth rate of per capita income on its initial level. One just needs to 
subtract one from the coefficient on the initial income level, while all standard errors remain unaffected. 
14 See Hahn and Hausman (2002) and Staiger and Stock (1997) for discussions of the weak-instrument problem 
and Arellano and Bond (1991) and Blundell and Bond (1998) for a discussion of increased efficiency of 
additional instruments.   14
Apart from the lagged dependent variable, we also use GMM instruments for the investment 
rate, which is suspected by Bhargava et al. (2001) to be endogenous. 
 
Table 3: Full Sample 







































































































































Income threshold  9719  16178 14475 14408  4578









# observations  286  320 320 341  341
Remarks: z-values applying Arellano (1987) covariance matrix in parenthesis; *, **, *** denotes significance 
level at the 10, 5, and 1 % level respectively; AR1 test on first order autocorrelation – p-value; AR2 test on 
second order autocorrelation p-value; heteroscedasticity consistent Hansen-test on overidentifying resrictions p-
value; Constant term not reported; 
 
The estimated coefficients have all the expected signs. However, some control variables are 
not or only weakly significant. The coefficient on lagged income appears fairly large with   15
large standard error. However, one needs to be careful not to mistake this coefficient for the 
convergence rate, since lagged income also appears in the interaction term. 
 
Turning to our variable of interest, the CVD variable and its interaction term are both 
significant at the 1 % level. At a threshold level of income below 9719 PPP US $, there is a 
positive impact of CVD mortality rates on growth, and above this threshold there is a negative 
relation. Such an income threshold is also found in Bhargava et al. (2001) with respect to 
adult survival rates. However, the income threshold for adult survival rates is much lower 
seperating poor from middle and high income countries, while the threshold for CVD 
seperates rich from middle and poor income countries in the classification of the World Bank. 
 
One needs to be careful in interpreting the relation of CVD and growth for three reasons. 
First, the test of second order autocorrelation of the estimated error term is weakly significant. 
This may render the covariate coefficient estimates inconsistent. Second, there may be reverse 
causality. Higher income growth may induce more luxury good consumption, which in turn 
could increase CVD mortality rates. Third, it may still be the case that there is no significant 
relation in one of the two sample halves, because the inclusion of the interaction term allows 
for a limited non-linearity only. In what follows we address all of these three possibilities. 
 
First, we allow for endogeneity of the CVD variable and its interaction term in specification 
(2). This excludes any inconsistency from reversed causality as long as there is no correlation 
of future values of CVD on todays error term in estimating growth. The income elasticity of 
CVD mortality rates is reduced by half. Hence, reversed causality is likely to exist, but cannot 
explain the correlation of CVD and economic growth alone. 
   16
So far, the estimates rely on large sample theory. In specification (3), we apply the more 
efficient two stage GMM estimator with small sample correction from Windmeijer (2000). 
Again, we do not observe any significant changes in results and obtain very similar estimates 
in magnitude. 
 
To finally have a comparison, we also apply in specification (4) an inconsistent OLS 
estimator and in specification (5) an inconsistent FE estimator. The t-values in parenthesis are 
calculated in both cases using an autocorrelation and heteroscedasticity consistent covariance 
matrix estimate of Arellano (1987). Since the openness variable from Gallup and Sachs 
(1998) has no time variation, it drops out in the FE specification. While coefficients are 
different in magnitude indicating the presence of a bias, the CVD variable and its interaction 
term remain significant in all specifications. 
 
When considering the implied income threshold at which there is a positive/negative 
correlation of CVD and income growth, the GMM estimators are in between the OLS and FE 
estimator. The implied threshold of the GMM estimators in roughly in the range that devides 
rich OECD and non-OECD from middle income countries according to the World Bank 
classification. For this reason, we continue analysing the rich-country sub-sample. 
 
When restricting the sample size, different control variables become relevant. Since the rich 
countries have unconstrained access to the international capital market, the fertility rate and 
the investment rate are no longer determinants of income growth. The fertility rate influences 
income growth, because, when entering the labor market, the newly born cohort needs to be 
endowed with capital to keep the capital intensity constant. This additional need for capital 
formation reduces the rate of net investment at a given savings rate in a closed economy. 
However, whenever there is access to an international capital markets, the additional capital   17
formation can be financed from abroad without being constrained by the domestic savings 
rate. In a similar vein, the investment rate is equal to the savings rate in a closed economy. 
Hence, economies with smaller savings rates invest less and grow less (Feldstein and Horioka, 
1980). This relation breaks down, when there is access to the international capital market.  
 







































































































































































Hansen-Test 0.99 0.99 0.96 0.99 0.99  -  -
AR1 0.00
*** 0.00




* 0.99 0.98 -  -
# 
observations 
164 164 141 143 143  143  143
Remarks: z-values applying Arellano (1987) covariance matrix in parenthesis; *, **, *** denotes significance 
level at the 10, 5, and 1 % level respectively; AR1 test on first order autocorrelation – p-value; AR2 test on 
second order autocorrelation p-value; heteroscedasticity consistent Hansen-test on overidentifying resrictions p-
value; Constant term not reported; 
   18
Indeed, the investment rate and the fertility rate turn out to be insignificant on the sub-sample 
of rich countries. In addition, the openness variable of Gallup and Sachs (1998) is also 
insignificant, which may be due to the lack of time variation of this variable. Instead, we 
apply the openness variable from the Penn World Tables, which is defined as the sum of 
imports and exports divided by GDP. Since GDP is part of the construction of the openness 
variable from the Penn World Tables, we will treat this variable as endogenous in GMM 
estimations. In addition, the share of the working age population with secondary education 
becomes a significant determinant of income growth, because human capital - unlike physical 
capital - is typically not mobile internationally.
15 
 
Table 4 displays the results on the rich-country sub-sample. First, we note that in specification 
(1) the CVD variable is highly significant with negative sign, when applying a GMM-one step 
estimator with endogenous CVD variable. Unfortunately, the autocorrelation test of second 
order indicates severe problems of autocorrelation, which renders the estimator inconsistent. 
To avoid this misspecification problem, we add in specification (2) an additional time lag of 
the dependent variable as covariate, but the autocorrelation problem remains. Since there is an 
additional lag of the dependent variable, all instruments are lagged by one more time, too, to 
avoid correlation of the instruments with the error term. 
 
Only, when we also add the third 5-year time lag of the dependent variable in specification 
(3), the problem of autocorrelation of the error term is substantially reduced. Still, when the 
CVD variable is assumed exogenous, there is autocorrelation at the 10% significance level. 
However, specification (4) endogenizes the CVD variable and the autocorrelation problem 
disappears. Hence, we consider this specification as our baseline, since it seems to be well 
specified: besides lack of autocorrelation of second order, the Hansen test of overidentifying 
                                                 
15 Bhargava et al. (2001) have pointed out that human capital measures are not significant in a panel data set with 
more countries.   19
restrictions is passed and the estimated coefficients are all significant with expected signs. For 
example, larger openness and a larger stock of human capital increase income growth. 
 
Our variable of interest, CVD, is also highly significant at the 5% level. An increase in the 
mortality rate by 1% decreases the per capita income growth rate by about one promille point. 
This is a small amount in terms of growth rates, but a large amount in money terms when 
summed up over the lifetime of an economy.  
 
Since the number of rich countries is rather small, it is important to apply the small sample 
correction of Windmeijer (2000) to the covariance estimates. Specification (5) displays the 
results. While openness becomes insignificant mainly due to a larger standard error, all other 
estimates remain significant. 
 
Finally, we report for the sake of comparison the estimates of an inconsistent OLS and FE 
estimator in specifications (6) and (7), respectively. While the magnitude of coefficients 
varies at times substantially indicating a presence of bias, the qualitative results remain the 
same, although the CVD variable is insignificant in the OLS specification. 
 
Since there seems to be a cyclical component in GDP growth data of a rather large wave 
length which seems puzzling at first glance, we also investigate the same data annually. To be 
able to do this, we need to interpolate the secondary schooling share variable first. Then, we 
find that autocorrelation disappears only if we include time lags of the dependent variable for 
the first four years, the 10
th year and the 15
th year both for the entire sample and the rich-
country sub-sample
16. Hence, the rather large cyclical pattern in the data is not an artefact of 
choosing five-year growth rates in the previous analysis. The first four year time lags 
                                                 
16 The results are not reported, but available from the authors upon request.   20
probably capture business cycle components of GDP growth. The larger lag length of 10 and 
15 years may be explained by Kondratieff-type technology waves. 
 
Next, we investigate the omitted variable problem. It may be that CVD mortality rates are 
correlated to an omitted variable that causes itself economic growth. For example, CVD 
mortality rates may be larger in societies with bad health systems which in turn may decrease 
the working moral, productivity, rate of return to investment, and eventually economic 
growth. Alternatively, it may be the case that the quality of the health system in general is 
itself a proxy variable for the quality of public intermediate goods supply. Finally, it may be a 
proxy for the innovative capability of an economy. 
 
For this reason, we apply a number of alternative measures of the health system as control 
variables. Since an additional variable implies an additional regression coefficient that must 
be estimated, the number of moment restrictions will be insufficient to have several time lags 
of the instruments. In order to avoid inefficiency of the estimates, when using only one 
instrument, we refer to the specification, when the CVD variable is assumed exogenous and 
the two first valid lacks of the instruments are applied. This procedure is justifiable, because 
we found in specifications (3) and (4) of Table 4 that the magnitude of the coefficient of the 
CVD variable is very similar in both cases. 
 
In Table 5, specification (1), we add the control variable adult mortality rate that has been 
used before already in Table 3. Next, we add the logarithm of the number of doctors per 
population in specification (2). The density of doctors can be thought of as a control for the 
coverage of the health system. In specification (3), we add the logarithm of the lagged 
mortality rate caused by injuries to control alternatively for the quality of the health system.   21
Specifications (4) and (5) eventually control for the lagged logarithm of the old age 
 
Table 5: Control variables OECD sample 






























































































































Lagged mortality rate  -0.02 
(-0.28) 
---  -









- - -0.01 
(-0.13)
- -
Lagged old age 
dependency ratio 
 






desease mortality rate 
- - - -  0.23
*
(1.78)
    





AR2 0.11  0.40 0.07
* 0.10
* 0.07
#  observations  141 130 141 141 141
Remarks: z-values applying Arellano (1987) covariance matrix in parenthesis; *, **, *** denotes significance 
level at the 10, 5, and 1 % level respectively; AR1 test on first order autocorrelation – p-value; AR2 test on 
second order autocorrelation p-value; heteroscedasticity consistent Hansen-test on overidentifying resrictions p-
value; Constant term not reported; 
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dependency rate, which may control for the innovative potential of an economy, and the 
lagged value of the mortality rate caused by non-communicable diseases to ensure that indeed 
cardiovascular disease is responsible for the relation with economic growth. 
 
In all cases, the CVD variable remains significant at the 5% level, while most of the control 
variables are not. The only exception is the old age dependency rate. Aging economies tend to 
grow slower. Overall, weak problems of autocorrelation remain in some specifications. Since 
the estimated coefficient of CVD remains remarkably stable over all specifications (with and 
without weak autocorrelation problems), we do not observe any substantial bias of its 
estimates even in the presence of weak autocorrelation. 
 
We also tried all estimates of Table 5 assuming the CVD variable to be endogenous
17. The 
CVD variable was always highly significant, but some other control variables became 
insignificant occasionally and some signs of control variables were not as expected. 
 
Finally, we investigate whether the CVD variable really does have the opposite sign in the 
sub-sample of middle and low-income countries (results not reported, but available on 
request). However, we find that no significant relationship exists in this sub-sample. Hence, 




The present paper has provided what is to the best of our knowledge the first attempt to assess 
the impact of cardiovascular disease on economic growth, using a growth regression 
framework. We used state-of-the-art methodology to address the most salient technical 
                                                 
17 The results are not reported but available from the authors upon request.   23
problems that could be addressed. There remains, however, a general concern about the 
application of the growth regression methodology (Durlauf, 2001). Data limitations matter, 
too: CVD mortality data, which we constructed on the basis of the WHO Mortality Database, 
is missing for many low-income countries, and where data is available, it is of significantly 
worse quality in the low- and middle-income countries compared to the high-income 
countries (WHO 2006). Hence our findings for the latter group of countries can be considered 
much more reliable than those for the low- and middle-income countries. 
Bearing in mind those reservations, the results suggest that CVDs are bad for growth, but only 
once the countries have reached a fairly high level of per capita income. It is not entirely 
surprising to note that CVDs have no statistically significant role in explaining growth 
differences between rich and poor countries in the time period examined (1960-2000). Too 
many other important factors distinguish the two country groups, and CVDs have only been 
emerging quite strongly in the later part of this period in developing countries. The result 
should therefore not be misinterpreted as a justification for complacency in the developing 
countries facing the fast growing burden of CVDs. Concern as for the potential future 
economic impact of CVDs in developing countries is particularly warranted in light of the 
fairly reliable prediction that not only the speed of the CVD epidemic in developing countries 
is likely to exceed that previously experienced by high-income-countries, but also that its 
adverse impacts are likely to be felt more strongly in the developing world (Schmidhuber and 
Shetty, 2005). 
 
Our results also contribute to the relatively small literature on the role of health as a 
determinant of growth in high-income countries. As briefly mentioned above, the empirical 
evidence on the role of health in economic growth in rich countries has produced rather 
unsatisfactory and mixed results, not least depending on the choice of health proxy. The very   24
few studies that used public health expenditure as a proxy for health did find a significant 
positive contribution to economic growth in high-income countries. However, in light of the 
poor empirical link between health expenditures and health outcomes (Anderson and Poullier, 
1999), one may have reason to question the interpretation of the results (Rivera and Currais 
(1999a, b), Knowles and Owen (1995, 1997)). In contrast, studies that used life expectancy as 
a proxy for health generally failed to find a significant impact on growth, and where the 
impact was significant, it was commonly of a negative sign. 
Our findings suggest that part of the ambiguous results may indeed be due to the choice of 
health proxy. As life expectancy varies very little between rich countries, it is not surprising to 
find that its explanatory power is highly limited. CVD-mortality (at working age) does vary 
more markedly between rich countries and therefore represents a more “appropriate” indicator 
to quantify existing health differences between rich countries. Nevertheless, the present study 
has only taken a first step towards an improved understanding of the “true” role of health in 
rich countries’ medium and long term growth performance. For certain, in order to better 
understand the contribution of health to economic development in rich countries, there is a 
critical need to go beyond the most general health indicators that have traditionally been 
applied in the developing country literature.  
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Appendix 
 
Table A 1: Summary Statistics – Full sample and Rich Country Sample 
Variable name  # observa-
tions 
Mean Std.  dev.  Min Max 
GDP p.c.  341  11365.32  6916.805  1369.589  33308.4 
1
st lag GDP p.c.  341  10109.32
  
6229.086 1121.392  28409.62 
Open 1965-90  341  0.5822242  .4552672  0  1 
Investment rate  341  20.90187  8.594127  3.249018  68.34639 
Fertility rate  341  2.968865  1.572043  1.18  7.4168 
Adult mortality rate  341  .011316  .0044232  .0052631  .0375629 
CVD mortality rate  341  134.7982  65.41324  32.61629  390.1721 
Openness 143  60.18594  47.53438  10.86745  301.3148 
Secondary education – total 
stock 
143  36.58671     12.75781       6.8  69.6 
Density of physicians  135  2.079481  .7873906       .6569  4.7 
Injury mortality rate – 
working age 
143  55.79993  16.82787    26.05  101.93 
Old age dependency rate  143  .1191733    .0299058  .033502  .1777936 
Non-communicable disease 
mortality rate 





Baseline Specification for Table 3 – Full sample. 
 
Argentina, Armenia, Australia, Austria, Azerbaijan, Belgium, Bulgaria, Belarus, Belize, 
Brazil, Barbados, Canada, Switzerland, Chile, China, Colombia, Costa Rica, Cuba, Czech 
Republic, Germany (united after 1990), Denmark, Dominican Republic, Ecuador, Egypt, 
Spain, Estonia, Finland, France, UK, Greece, Guatemala, Hong Kong, Honduras, Croatia, 
Hungary, Ireland, Iceland, Israel, Italy, Jamaica, Japan, Kazakhstan, Kyrgyzstan, Republic 
Korea, Sri Lanka, Lithuania, Luxembourg, Latvia, Moldova, Mexico, Mauritius, Netherlands, 
Norway, New Zealand, Panama, Philippines, Poland, Puerto Rico, Portugal, Paraguay, 
Romania, Russia, Singapore, El Salvador, Slovenia, Sweden, Syria, Thailand, Trinidad and 
Tobago, Ukraine, Uruguay, USA, Venezuela. 
 
 
Baseline specification for Table 4 and 5 – high income and higher-middle income 
countries according to World Bank classification. 
Australia, Austria, Belgium, Canada, Czech Republic, Germany (united from 1990), 
Denmark, Spain, Finland, France, UK, Greece, Hong Kong, Irland, Isalnd, Israel, Italy, 
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